© 2023 MJH Life Sciences and Cancer Network. All rights reserved.
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
November 10, 2022
Closing out their review of metastatic urothelial carcinoma management, panelists share what they most look forward to in the evolving treatment landscape.
November 03, 2022
Focused discussion on the optimal selection and use of antibody-drug conjugate therapies in patients with metastatic urothelial carcinoma.
Expert perspectives on treatment sequencing pathways in metastatic urothelial carcinoma, with deference to recent trial data for both IO and ADC therapies.
October 27, 2022
The panel reviews a clinical scenario of metastatic urothelial carcinoma where the patient is not eligible for cisplatin treatment.
A comprehensive review of maintenance therapy strategies following chemotherapy in the context of optimizing patient outcomes.
October 20, 2022
Centering discussion on a clinical scenario of metastatic urothelial carcinoma, panelists determine which first-line regimen they would utilize prior to maintenance therapy.
A panel of experts reviews key clinical trial data supporting use of maintenance therapy in metastatic urothelial carcinoma.
October 13, 2022
Shared insight on the broader benefits of maintenance therapy in metastatic urothelial carcinoma and the mainstay agents in this setting.
Expert oncologists provide a comprehensive overview of treatment options available to patients with metastatic urothelial carcinoma.
October 06, 2022
A brief review of both neoadjuvant and adjuvant treatment options available to patients with localized bladder cancer.